Jon Congleton - 29 Jun 2026 Form 4 Insider Report for IMMUNIC, INC. (IMUX)

Reporting relationship: Director
Issuer ticker: IMUX
Reported as of: 29 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 29 Jun 2026, 16:34:34 UTC
Prior SEC filing: 29 Apr 2026
Next SEC filing: 30 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Grant Levine, attorney-in-fact

Key filing fact

Jon Congleton filed Form 4 for IMMUNIC, INC. (IMUX) on 29 Jun 2026.

Key facts

This page summarizes Jon Congleton's Form 4 filing for IMMUNIC, INC. (IMUX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 29 Jun 2026, 16:34.

Change

Previous filing in this sequence was filed on 29 Apr 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001644975 Primary reporting owner

Congleton Jon

Relationship: Director
Address: 1200 AVENUE OF THE AMERICAS, SUITE 200, NEW YORK
Signature: /s/ Grant Levine, attorney-in-fact
Signature date: 29 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IMUX transaction Derivative

Stock Option

Award

Transaction value
Shares: +50,740
Change %
Price: $0.000000^*
Shares after: 50,740
Date: 29 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 50,740
Exercise price: $10.90
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents options to purchase shares of common stock conditionally approved by the Board of Directors on March 27, 2026, subject to approval of an amendment to the Company's 2019 Omnibus Equity Incentive Plan, as amended, by the Company's stockholders, which approval was obtained at the Company's 2026 Annual Meeting of Stockholders held on June 29, 2026.

Footnote F2

The options vest in thirty-six (36) equal installments on each monthly anniversary of March 27, 2026.